Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12622000621718
Ethics application status
Approved
Date submitted
11/04/2022
Date registered
27/04/2022
Date last updated
10/05/2023
Date data sharing statement initially provided
27/04/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
Prospective registry for geniculate arterial embolisation as treatment for osteoarthritis and neovascularity.
Query!
Scientific title
PRAETORIAN: Prospective Registry for geniculate Arterial Embolisation as Treatment for OsteoaRthrItis And Neovascularity
Query!
Secondary ID [1]
306901
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PRAETORIAN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Knee osteoarthritis
326009
0
Query!
Condition category
Condition code
Musculoskeletal
323314
323314
0
0
Query!
Osteoarthritis
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
True
Query!
Target follow-up duration
12
Query!
Target follow-up type
Months
Query!
Description of intervention(s) / exposure
Genicular artery embolisation (GAE) or embolisation of the knee is a minimally-invasive procedure used to reduce pain caused by knee osteoarthritis (KOA).
We aim to establish a prospective registry to collect evidence on the safety and effectiveness of GAE in two distinct patient groups: a) patients experiencing moderate-to-severe persistent chronic pain due to neovascularization or haemarthrosis following total knee arthroplasty (TKA), and b) patients with moderate-to-severe KOA refractory to conservative or medical therapies who are not currently suitable total knee arthroplasty (TKA) candidates.
Patients referred by orthopaedic consultants (following the start date of the registry) to undergo GAE will be approached to be included in the registry. During the screening, the investigators will describe the nature of the patient registry and assess potential participants’ eligibility according to the registry’s inclusion/exclusion criteria. Eligible participants will be provided with a Patient Information and Consent Form (PICF). Participation in the prospective registry will be voluntary and potential participants will be given enough time to decide whether or not to take part in the registry. Referred patients will undergo the GAE procedure (per the investigational site’s standard of care) irrespective of their decision. Examinations, evaluations, treatment and hospital discharge procedures will be conducted per the investigational site’s standard of care.
Registry subjects are to be followed according to the investigational sites’ standard of care practices. There are no additional treatments or scans to be performed for the purpose of this registry. The only difference between the routine clinical practice and this registry is that participants will be asked to complete an online questionnaire at baseline and 6 and 12 months (±2 weeks) post-GAE for the registry. The anticipated time needed to complete the online questionnaire at each time point is 25 minutes.
The subject’s following information will be collected (directly from their health records and/or via a Data Collection form) for the registry:
- Demographic information (e.g. date of birth, sex, BMI, etc.)
- Medical history and list of medication
- FBC and U&E blood test results
- Knee radiographs and magnetic resonance imaging (MRI) results and interpretations. Imaging will be usually performed prior to GAE and may be repeated at the follow-up consultation at 3 months (±2 weeks) as per the investigational site’s standard of care
- Procedural information (e.g. type of embolic used, length of the procedure, injected contrast volume, skin dose, amount of embolic used, etc.)
- Adverse events (AEs) will be documented immediately after the GAE procedure and at the follow-up consultation at 3 months (±2 weeks) as per the investigational site’s standard of care. Each AE will be classified for its severity, or the intensity of an event, experienced by the subject
The online questionnaire will consist of the validated and standardised questionnaires used by the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) for patients undergoing knee replacement procedures. These include:
1. EQ-5D-5L questionnaire. The EQ-5D-5L is a standardised instrument for measuring overall health status. The descriptive system is comprised of 5 dimensions: mobility, personal care, usual activities, pain/discomfort and anxiety/depression.
2. EQ VAS. The EQ VAS is a validated self-rated health instrument. Patients are asked to indicate their current health status on a scale from 0 (the worst health patient can imagine) to 100 (the best health patient can imagine).
3. Oxford Knee Score. The Oxford Knee Score (OKS) is a standardised and validated patient-reported outcomes (PROMs) instrument developed to assess function and pain in patients undergoing knee surgery. The OKS provides a single summed score; the lower the scoring, the higher the severity of the patient’s problems.
4. KOOS-12. The KOOS-12 instrument is a 12-item measure derived from the original Knee Injury and Osteoarthritis Outcome Score (KOOS). KOOS-12 contains 4 KOOS Pain items, 4 KOOS Function (Activities of Daily Living and Sport/Recreation) items, and 4 KOOS Quality of Life (QOL) items. KOOS-12 reduces respondent burden by 70% from the original KOOS while providing scale scores for knee-specific pain, function and QoL, along with a summary measure of overall knee impact. To interpret KOOS scoring, the outcome measure is a scale from worst to best from 0 to 100, with 100 indicating no symptoms and 0 indicating extreme symptoms.
5. Average pain scale (last 7 days). Patients will use a scale to indicate the average knee joint pain they had experienced over the last 7 days (from 0: no pain at all to 10: the worst pain imaginable).
6. Expectation questions. Patients will be asked their expectations for pain, mobility, and health in 6 and 12 months’ time at the pre-operative collection point. At the post-GAE collection point, patients will rate their perceptions based on that day.
7. Satisfaction and joint change questions. At 6 and 12 months post-GAE timepoints, patients will be asked to describe how satisfied they are with the results of their procedures and their perceived change in the problems associated with their knee.
8. Side effects/Complications question. At 6 and 12 months post-GAE timepoints, patients will be asked to describe whether they experienced any side effects/complications following GAE.
The use of these questionnaires will allow us to directly compare GAE results with those collected from patients undergoing total knee replacement procedures from the National Joint Registery. The direct comparison is expected to provide crucial information for orthopaedic surgeons and affect future KOA pain management plans.
Query!
Intervention code [1]
323351
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
The outcome of the questionnaires used in this registry will be compared to those collected from patients undergoing total knee replacement procedures by the Australian Orthopaedic Association National Joint Replacement Registry.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
331051
0
Safety of the genicular artery embolisation (GAE) procedure measured by occurrence of adverse events as reported by the patient and investigators.
Whilst severe or long-term complications are very rare, the most consistently reported side effect of GAE is non-target embolisation to the overlying skin resulting in temporary skin discoloration over the embolised territory. Other reported adverse events include moderate subcutaneous hemorrhage at the puncture site, small self-limiting groin hematoma, transient mild knee pain, self-resolving focal skin ulceration, and asymptomatic small bone infarct.
Query!
Assessment method [1]
331051
0
Query!
Timepoint [1]
331051
0
Assessed immediately after the GAE procedure and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Primary outcome [2]
331052
0
Overall efficacy of the genicular artery embolisation (GAE) procedure. This is a composite outcome. It is determined based on the results obtained from the changes in overall and current health status; patient-reported outcomes (PROMs); average knee joint pain; patient satisfaction and problems following GAE procedure; and patient expectations for pain, mobility, and health. These data will be collected from the study questionnaire.
Query!
Assessment method [2]
331052
0
Query!
Timepoint [2]
331052
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [1]
408598
0
Change in overall health status measured by EQ-5D-5L questionnaire.
Query!
Assessment method [1]
408598
0
Query!
Timepoint [1]
408598
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [2]
408599
0
Change in current health status measured EQ VAS scale.
Query!
Assessment method [2]
408599
0
Query!
Timepoint [2]
408599
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [3]
408600
0
Change in patient-reported outcomes (PROMs) measured by Oxford Knee Score (assesses function and pain) questionnaire.
Query!
Assessment method [3]
408600
0
Query!
Timepoint [3]
408600
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [4]
408601
0
Change in patient-reported outcomes (PROMs) measured by KOOS-12 (assesses pain, function, and quality of life) questionnaire (the questionnaire was amended to suit GAE procedure).
Query!
Assessment method [4]
408601
0
Query!
Timepoint [4]
408601
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [5]
408602
0
Change in average knee joint pain, measured by Visual Analogue Scale (VAS).
Query!
Assessment method [5]
408602
0
Query!
Timepoint [5]
408602
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [6]
408603
0
Patient expectation for pain, measured by an online question that was previously used by the Australian Orthopaedic Association National Joint Replacement Registry (the question was amended to suit the GAE procedure).
Query!
Assessment method [6]
408603
0
Query!
Timepoint [6]
408603
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [7]
408604
0
Patient satisfaction following the GAE procedure, measured by an online question that was previously used by the Australian Orthopaedic Association National Joint Replacement Registry (the question was amended to suit the GAE procedure).
Query!
Assessment method [7]
408604
0
Query!
Timepoint [7]
408604
0
Assessed at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [8]
408605
0
Current status of problems associated with knee joint following the GAE procedure, measured by an online question that was previously used by the Australian Orthopaedic Association National Joint Replacement Registry (the question was amended to suit the GAE procedure).
Query!
Assessment method [8]
408605
0
Query!
Timepoint [8]
408605
0
Assessed at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [9]
408932
0
Patient expectation for mobility, measured by an online question that was previously used by the Australian Orthopaedic Association National Joint Replacement Registry (the question was amended to suit the GAE procedure).
Query!
Assessment method [9]
408932
0
Query!
Timepoint [9]
408932
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Secondary outcome [10]
408933
0
Patient expectation for their health, measured by an online question that was previously used by the Australian Orthopaedic Association National Joint Replacement Registry (the question was amended to suit the GAE procedure).
Query!
Assessment method [10]
408933
0
Query!
Timepoint [10]
408933
0
Assessed at baseline (pre-GAE), and at 6 and 12 months (±2 weeks) post GAE procedure.
Query!
Eligibility
Key inclusion criteria
Inclusion criteria for group A (patients with moderate-to-severe chronic pain following TKA):
- Age 40 yrs or older who are willing and able to provide informed consent
- Experiencing ongoing moderate to severe pain for at least 6 months after total knee arthroplasty
- and having failed conservative medical treatment for at least 6 months (e.g. physiotherapy/anti-inflammatory/analgesia/masso-kinesiotherapy, etc.)
Inclusion criteria for group B (patients with moderate-to-severe KOA):
- Age 40 yrs or older who are willing and able to provide informed consent
- Presence of moderate to severe knee OA as stipulated by referring orthopedic surgeon
- Presence of knee pain for at least 6 months, resistant to conservative treatments (e.g. physiotherapy, analgesia, exercise, weight loss, intra-articular injections, etc.)
- Non-surgical candidates: ineligible/refused total knee arthroplasty (TKA)
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria for group A (patients with moderate-to-severe chronic pain following TKA):
- Rheumatoid, infectious arthritis, osteonecrosis, or advanced atherosclerosis
- Malignancy
- Renal impairment (eGFR <45)
- A bleeding diathesis
- Irreversible coagulopathy
- Re-operation
- Allergic to contrast media
Exclusion criteria for group B (patients with moderate-to-severe KOA):
- Rheumatoid, infectious arthritis, osteonecrosis, or advanced atherosclerosis
- Malignancy
- Renal impairment (eGFR <45)
- A bleeding diathesis
- Irreversible coagulopathy
- Allergic to contrast media
Query!
Study design
Purpose
Screening
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
This will be a prospective registry designed to collect and analyse sufficient patient data to confirm the efficacy and safety of a pre-existing procedure that is attracting increased clinical use globally.
The safety (i.e. number and percentage of adverse outcomes) and GAE efficacy will be determined by evaluating data obtained from pre-procedural, intra-procedural and post-procedural timepoints. Questionnaire data collected at baseline and 6 and 12 months post-GAE procedure will be analysed using appropriate statistical tests to determine the efficacy of GAE for pain management. In addition, obtained results will be compared to those collected by the Australian Orthopaedic Association National Joint Replacement Registry. This will allow us to perform a direct comparison analysis, which will provide crucial information about the safety and effectiveness of GAE compared to knee replacement procedures. Descriptive statistics will be used as appropriate, for example, when presenting data on patient characteristics such as mean, median and range of patient age and BMI.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
8/05/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
14/02/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
14/02/2025
Query!
Actual
Query!
Sample size
Target
150
Query!
Accrual to date
0
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
22186
0
The Wesley Hospital - Auchenflower
Query!
Recruitment hospital [2]
22187
0
St Andrew's War Memorial Hospital - Brisbane
Query!
Recruitment hospital [3]
22188
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [4]
22189
0
Sunshine Coast University Private Hospital - Birtinya
Query!
Recruitment postcode(s) [1]
37340
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [2]
37341
0
4000 - Brisbane
Query!
Recruitment postcode(s) [3]
37342
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
37343
0
4575 - Birtinya
Query!
Funding & Sponsors
Funding source category [1]
311214
0
Commercial sector/Industry
Query!
Name [1]
311214
0
Bio-Excel
Query!
Address [1]
311214
0
1/29 Governor Macquarie Drive
Chipping Norton NSW 2170
Australia
Query!
Country [1]
311214
0
Australia
Query!
Funding source category [2]
311216
0
Commercial sector/Industry
Query!
Name [2]
311216
0
I-MED Radiology Network
Query!
Address [2]
311216
0
Wesley Specialist Centre
Level 1
87 Lang Pde
Auchenflower
QLD
4066
Query!
Country [2]
311216
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
I-MED Radiology Network
Query!
Address
Wesley Specialist Centre
Level 1
87 Lang Pde
Auchenflower
QLD
4066
Query!
Country
Australia
Query!
Secondary sponsor category [1]
312583
0
None
Query!
Name [1]
312583
0
Query!
Address [1]
312583
0
Query!
Country [1]
312583
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
310742
0
UnitingCare Human Research Ethics Committee
Query!
Ethics committee address [1]
310742
0
UnitingCare Health Human Research Ethics Committee
Ground Floor Moorlands House
The Wesley Hospital
451 Coronation Drive, Auchenflower QLD 4066
PO Box 499 Toowong QLD 4066
Query!
Ethics committee country [1]
310742
0
Australia
Query!
Date submitted for ethics approval [1]
310742
0
07/01/2022
Query!
Approval date [1]
310742
0
20/05/2022
Query!
Ethics approval number [1]
310742
0
202201
Query!
Summary
Brief summary
Genicular artery embolisation (GAE) or embolisation of the knee is a minimally-invasive procedure used to reduce pain caused by KOA. GAE is a legitimate course of treatment for patients referred by their orthopaedic surgeons who meet the inclusion criteria. A small number of human studies investigating GAE in patients with knee osteoarthritis (KOA) have been conducted in Australia and internationally. We seek to establish a prospective registry on GAE to consolidate local experiences and collect evidence to affirm the safety and efficacy of GAE procedure in patients experiencing moderate-to-severe persistent chronic pain following total knee arthroplasty (TKA) and also those with moderate-to-severe knee OA who are not yet suitable for surgical intervention.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
118710
0
Dr Nicholas Brown
Query!
Address
118710
0
I-MED Radiology
Level 2 Sandford Jackson Building
The Wesley Hospital
30 Chasely St
Auchenflower
QLD
4066
Query!
Country
118710
0
Australia
Query!
Phone
118710
0
+61403 324 362
Query!
Fax
118710
0
Query!
Email
118710
0
[email protected]
Query!
Contact person for public queries
Name
118711
0
Dr Sepinoud Firouzmand
Query!
Address
118711
0
I-MED Radiology
Wesley Specialist Centre
Level 1
87 Lang Pde
Auchenflower
QLD
4066
Query!
Country
118711
0
Australia
Query!
Phone
118711
0
+61 7 3371 9588
Query!
Fax
118711
0
Query!
Email
118711
0
[email protected]
Query!
Contact person for scientific queries
Name
118712
0
Dr Sepinoud Firouzmand
Query!
Address
118712
0
I-MED Radiology
Wesley Specialist Centre
Level 1
87 Lang Pde
Auchenflower
QLD
4066
Query!
Country
118712
0
Australia
Query!
Phone
118712
0
+61 7 3371 9588
Query!
Fax
118712
0
Query!
Email
118712
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
It is not anticipated that patient information will be shared outside the registry investigator group.
Publishing/sharing of de-identified data via conference presentations or journal articles is planned to share the cohort data publicly.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF